These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 19148858)

  • 1. [Heart failure with thiazolidinedione treatment: what do we know today?].
    Erdmann E
    Dtsch Med Wochenschr; 2009 Jan; 134(4):154-8. PubMed ID: 19148858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.
    Nesto RW; Bell D; Bonow RO; Fonseca V; Grundy SM; Horton ES; Le Winter M; Porte D; Semenkovich CF; Smith S; Young LH; Kahn R; ;
    Circulation; 2003 Dec; 108(23):2941-8. PubMed ID: 14662691
    [No Abstract]   [Full Text] [Related]  

  • 3. Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits.
    Patel RR
    Cardiol Rev; 2009; 17(3):132-5. PubMed ID: 19384087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?
    Buckingham RE; Hanna A
    Diabetes Obes Metab; 2008 Apr; 10(4):312-28. PubMed ID: 18333890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure.
    Erdmann E; Wilcox RG
    Eur Heart J; 2008 Jan; 29(1):12-20. PubMed ID: 18167366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Heart failure while taking glitazones--what do we know today?].
    Halbritter R
    Dtsch Med Wochenschr; 2009 Jul; 134(28-29):1488; author reply 1488. PubMed ID: 19572255
    [No Abstract]   [Full Text] [Related]  

  • 8. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Glitazones and congestive heart failure: update on PROactive, ADOPT, DREAM and RECORD clinical trials].
    De Flines J; Scheen AJ
    Rev Med Suisse; 2007 Aug; 3(122):1876, 1878-83. PubMed ID: 17896661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of glitazones in management of type 2 diabetes. A dream or a nightmare?
    Lindberg M; Astrup A
    Obes Rev; 2007 Sep; 8(5):381-4. PubMed ID: 17716295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rough road for rosiglitazone.
    Goldfine AB
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality.
    Stafylas PC; Sarafidis PA; Lasaridis AN
    Int J Cardiol; 2009 Jan; 131(3):298-304. PubMed ID: 18684530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC
    J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.
    Dahabreh IJ; Economopoulos K
    Clin Trials; 2008; 5(2):116-20. PubMed ID: 18375649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study.
    Hartung DM; Touchette DR; Bultemeier NC; Haxby DG
    Pharmacotherapy; 2005 Oct; 25(10):1329-36. PubMed ID: 16185176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.
    Grossman LD; Parlan G; Bailey AL; Yee G; Yu M; Chan JY
    Clin Ther; 2009 Jan; 31(1):74-88. PubMed ID: 19243708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk and cardiometabolic protection: role of glitazones.
    Petrazzi L; Grassi D; Polidoro L; D'Aurelio A; Croce G; Properzi G; Tiberti S; Desideri G; Ferri C
    J Nephrol; 2008; 21(6):826-35. PubMed ID: 19034866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
    Fisman EZ; Tenenbaum A; Motro M; Adler Y
    Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.